|
1
|
Balu-Maestro C, Chapellier C, Souci J,
Caramella T and Marcotte-Blonch C: Breast cancer screening imaging:
what do we do. J Gynecol Obstet Biol Reprod (Paris). 39:3–10.
2010.(In French). View Article : Google Scholar
|
|
2
|
French Institute for Public Health
Surveillance; National Cancer Institute France. Projection of the
incidence and mortality of cancer in France in 2011. Technical
report. French Institute for Public Health Surveillance;
Saint-Maurice: pp. 782011
|
|
3
|
Dinshaw KA, Budrukkar AN, Chinoy RF, Sarin
R, Badwe R, Hawaldar R and Shrivastava SK: Profile of prognostic
factors in 1022 Indian women with early-stage breast cancer treated
with breast-conserving therapy. Int J Radiat Oncol Biol Phys.
63:1132–1141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sánchez-Muñoz A, Ribelles N and Alba E:
Optimal adjuvant hormonal therapy in postmenopausal women with
hormone-receptor-positive early breast cancer: have we answered the
question? Clin Transl Oncol. 12:614–620. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mouridsen HT and Robert NJ: The role of
aromatase inhibitors as adjuvant therapy for early breast cancer in
postmenopausal women. Eur J Cancer. 41:1678–1689. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grau JJ, Zanon G, Caso C, Gonzalez X,
Rodriguez A, Caballero M and Biete A: Prognosis in women with
breast cancer and private extra insurance coverage. Ann Surg Oncol.
20:2822–2827. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mereno-Aspitia A, Hillman DW, Dyar SH,
Tenner KS, Gralow J, Kaufman PA, et al: Soluble human epidermal
growth factor receptor 2 (HER2) levels in patients with
HER2-positive breast cacner receiving chemotherapy with or without
trastuzumab: results from North Central Cancer Treatment Group
adjuvant trail N9831. Cancer. 119:2675–2682. 2013. View Article : Google Scholar
|
|
8
|
Swenson KK, Decher L, Haselow R, Farrell
JB and Sperduto PW: Prognostic factors after conservative surgery
and radiation therapy for early stage breast cancer. Am J Clin
Oncol. 21:111–116. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cianfrocca M and Goldstein LJ: Prognostic
and predictive factors in early-stage breast cancer. Oncologist.
9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harvey EB and Brinton LA: Second cancer
following cancer of the breast in Connecticut, 1935-82. Natl Cancer
Inst Monogr. 68:99–112. 1985.PubMed/NCBI
|
|
11
|
Chen Y, Thompson W, Semenciw R and Mao Y:
Epidemiology of contralateral breast cancer. Cancer Epidemio
Biomakers Prev. 8:855–861. 1999.
|
|
12
|
Wolff AC, Hammond ME, Hicks DG, et al:
Recommendations for human epidermal growth factor receptor 2
testing in breast cancer: American Society of Clinical
Oncology/College of American Pathologists clinical practice
guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao X, Fisher SG and Emami B: Risk of
second primary cancer in the contralateral breast in women treated
for early-stage breast cancer: a population-based study. Int J
Radiat Oncol Biol Phys. 56:1038–1045. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Broët P, de la Rochefordière A, Scholl SM,
Fourquet A, Mosseri V, Durand JC, et al: Contralateral breast
cancer: annual incidence and risk parameters. J Clin Oncol.
13:1578–1583. 1995.PubMed/NCBI
|
|
15
|
Mariani L, Coradini D, Biganzoli E,
Boracchi P, Marubini E, Pilotti S, et al: Prognostic factors for
metachronous contralateral breast cancer: a comparison of the
linear Cox regression model and its artificial neural network
extension. Breast Cancer Res Treat. 44:167–178. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reiner AS, John EM, Brooks JD, Lynch CF,
Bernstein L, Mellemkjær L, et al: Risk of asynchronous
contralateral breast cancer in noncarriers of BRCA1 and BRCA2
mutations with a family history of breast cancer: a report from the
Women’s Environmental Cancer and Radiation Epidemiology Study. J
Clin Oncol. 31:433–439. 2013. View Article : Google Scholar :
|
|
17
|
Yadav BS, Sharma SC, Patel FD, Ghoshal S
and Kapoor RK: Second primary in the contralateral breast after
treatment of breast cancer. Radiother Oncol. 86:171–176. 2008.
View Article : Google Scholar
|
|
18
|
Lizarraga IM, Sugg SL, Weigel RJ and
Scott-Conner CE: Review of risk factors for the development of
contralateral breast cancer. Am J Surg. 206:704–708. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sutherland CM and Mather FJ: Long-term
survival and prognostic factors in patients with regional breast
cancer (skin, muscle, and/or chest wall attachment). Cancer.
55:1389–1397. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Claus EB, Stowe M, Carter D and Holford T:
The risk of a contralateral breast cancer among women diagnosed
with ductal and lobular breast carcinoma in situ: data from the
Connecticut Tumor Registry. Breast. 12:451–456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dalberg K, Johansson H, Johansson U and
Rutqvist LE: A randomized trial of long term adjuvant tamoxifen
plus postoperative radiation therapy versus radiation therapy alone
for patients with early stage breast carcinoma treated with
breast-conserving surgery. Stockholm Breast Cancer Study Group.
Camcer. 82:2204–2211. 1998.
|
|
22
|
Clarke MJ: WITHDRAWN: Tamoxifen for early
breast cancer. Cochrane Database Syst Rev. 8:CD0004862008.
|
|
23
|
Phillips KA, Milne RL, Rookus MA, Daly MB,
Antoniou AC, Peock S, et al: Tamoxifen and risk of contralateral
breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol.
31:3091–3099. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khan AJ, Parikh RR, Neboori HJ, Goyal S,
Haffty BG and Moran MS: The relative benefits of tamoxifen in older
women with T1 early-stage breast cancertreated with
breast-conserving surgery and radiation therapy. Breast J.
19:490–495. 2013.PubMed/NCBI
|
|
25
|
Annecke K, Schmitt M, Euler U, Zerm M,
Paepke D, Paepke S, et al: uPA and PAI-1 in breast cancer: review
of their clinical utility and current validation in the prospective
NNBC-3 trial. Adv Clin Chem. 45:31–45. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lamy PJ, Romieu G and Jacot W: UPA/PAI-1:
a tool for breast cancer treatment individualization. Biology,
clinical implications and quantification assays. Bull Cancer.
97:341–348. 2010.(In French). PubMed/NCBI
|
|
27
|
Eljuga D, Razumovic JJ, Bulic K,
Petrovecki M, Draca N and Bulic SO: Prognostic importance of PAI-1
in node negative breast cancer patients - results after 10 years of
follow up. Pathol Res Pract. 207:290–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schmitt M, Mengele K, Napieralski R,
Magdolen V, Reuning U, Gkazepis A, et al: Clinical utility of
level-of-evidence-1 disease forecast cancer biomakers uPA and its
inhibitor PAI-1. Expert Rev Mol Diagn. 10:1051–1067. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kantelhardt EJ, Vetter M, Schmidt M,
Veyret C, Augustin D, Hanf V, et al: Prospective evaluation of
prognostic factors uPA/PAI-1 in node-negative breast cancer: phase
III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus
3×FEC/3×Docetaxel. BMC Cancer. 11:1402011. View Article : Google Scholar
|
|
30
|
Dazzi C, Cariello A, Maioli P, Magi S,
Rosti G, Giovanis P, et al: A high cytosol value of urokinase-type
plasminogen activator (uPA) may be predictive of early relapse in
primary breast cancer. Cancer Invest. 21:208–216. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rubino C, de Vathaire F, Diallo I,
Shamsaldin A and Lê MG: Increased risk of second cancers following
breast cancer: role of the initial treatment. Breast Cancer Res
Treat. 61:183–195. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schaapveld M, Visser O, Louwman MJ, de
Vries EG, Willemse PH, Otter R, et al: Risk of new primary
nonbreast cancers after breast cancer treatment: a Dutch
population-based study. J Clin Oncol. 26:1239–1246. 2008.
View Article : Google Scholar : PubMed/NCBI
|
